Current Report Filing (8-k)
August 07 2017 - 4:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2017
Dynavax Technologies Corporation
(Exact name of registrant as specified in its charter)
Commission
File Number: 001-34207
|
|
|
Delaware
|
|
33-0728374
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification No.)
|
2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)
(510) 848-5100
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On August 3, 2017, Dynavax Technologies Corporation issued a press
release titled Dynavax Provides U.S. Regulatory Update on
HEPLISAV-B
Following FDA Advisory Committee Meeting. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated
herein by reference.
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits. The following exhibit is filed
herewith:
|
|
|
99.1
|
|
Press Release, dated August 3, 2017, titled Dynavax Provides U.S. Regulatory Update on
HEPLISAV-B
Following FDA Advisory Committee Meeting
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Dynavax Technologies Corporation
|
|
|
|
|
Date: August 7, 2017
|
|
|
|
By:
|
|
/s/ STEVEN N. GERSTEN
|
|
|
|
|
|
|
Steven N. Gersten
|
|
|
|
|
|
|
Vice President
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
EX-99.1
|
|
Press Release, August 3, 2017, titled Dynavax Provides U.S. Regulatory Update on
HEPLISAV-B
Following FDA Advisory Committee Meeting
|
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024